Inhibitory Effect of Abatacept against Joint Inflammation Shown by Ultrasound Power Doppler Scoring in Japanese Bio-Naive Patients with Rheumatoid Arthritis

Not Applicable

• Conditions: Rheumatoid Arthritis

• Registration Number: JPRN-UMIN000042934
• Lead Sponsor: Hirosaki University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-01-07
• Study Completion: 2021-09-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients who are suffering from severe infectious disease. 2.Patients with lymphocytes less than 500/microL and high levels of beta-D glucan 3.Patients who are infected EB virus or HBV 4.Patients who are unsuitable to participate in this study by attending physicians.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
-Improvement rate of PDUS score in Abatacept dose 8 weeks later

Secondary Outcome Measures

Name	Time	Method
-Improvement rate of PDUS score in Abatacept dose 24 and 48 weeks later -Relevance between the improvement rate of pain score and PDUS score in Abatacept dose 0, 2, 4, 8, 24, 48 weeks later -Transition of disease activity in Abatacept dose 0, 2, 4, 8, 24, 48 weeks later -Relevance between ACPA, RF, Cytokine expression levels and improvement rate of PDUS score, pain score, disease activity